Caris Life Sciences vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Caris Life Sciences provides comprehensive molecular profiling of tumors to guide cancer treatment decisions, with one of the largest oncology biomarker databases.
About
Caris Life Sciences is a precision oncology company founded in 1998 and headquartered in Irving, Texas, that provides comprehensive molecular profiling tests used by oncologists to select personalized cancer treatments. The company's flagship test Molecular Intelligence analyzes tumors using whole transcriptome sequencing, whole exome sequencing, and protein expression to identify biomarkers that predict response to specific therapies including targeted drugs and immunotherapies. Caris has built one of the largest real-world oncology molecular databases, with profiles from hundreds of thousands of patient tumors that are used for research, drug development partnerships, and AI model training. The company serves oncologists, cancer centers, and pharmaceutical companies conducting biomarker-driven clinical trials. Caris has raised over $1B and operates CLIA-certified laboratory facilities in Phoenix and Irving. The company's database and AI capabilities have attracted partnerships with pharmaceutical companies seeking to identify patient populations most likely to respond to novel therapies. Caris positions itself at the intersection of clinical diagnostics and drug development infrastructure, generating value both from patient care and from the insights its large clinical database enables.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.